Ras Al Khaimah, United Arab Emirates -Sunday, March 26th 2017 [ ME NewsWire ]
Commenting on the appointment of Jerome Carle as Acting General Manager, His Highness Sheikh Faisal Bin Saqr Al Qassimi, Chairman of Julphar, said: “The Board believes that Jerome is the right person to drive Julphar while we are looking for a new and highly qualified candidate to fill the CEO role, and we are grateful for Jerome’s readiness to endorse the role at this time. I want to thank Dr Ayman Sahli for his outstanding service to the company the past eight years, and I personally wish him well in the future."
Jerome Carle commented: “I would like to thank the Board of Directors for their trust. I am looking forward to working under their guidance. Together with the Executive team, I am confident that we will prepare a smooth transition until our new CEO is appointed and ensure that Julphar is in the right direction to reach our 2020 vision.”
About Julphar
Established in 1980, Julphar is the largest generic pharmaceutical manufacturer in Middle East and North Africa, producing over 200 branded products across its fifteen manufacturing facilities. Julphar’s mission is to offer high quality medicines at affordable prices, and its product portfolio includes: Wound Care & Biotechnology, Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care. In 2012 Julphar launched Julphar Diabetes, a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility that has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA). Julphar employs approximately 3,000 people around the world and registered sales revenue of AED 1.47 billion in the year ending 2015. For more information, please visit http://www.julphar.net.
Contacts
Mehtap Teke
Corporate Communication Manager, +971-7-204-5209
M +971-55-1934619, mehtap.teke@julphar.net
Permalink : http://me-newswire.net/news/3615/en
No comments:
Post a Comment